Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Trastuzumab Biosimilar Market size is poised to witness lucrative growth rate during the forecast period i.e., between 2025-2037.
Extensive research associated with cancer treatment in western countries, along with the growing investment in the development of advanced therapies are expected to fuel the progress of this market. The growth of the market can also be attributed to factors such as the increasing geriatric population and changing lifestyle. According to the data collected from World Health Organization, in 2020, cancer was the leading cause of death worldwide, accounting for nearly 10 million deaths.
Trastuzumab Biosimilar Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Prevalence of Cancer
- Increasing Geriatric Population in the World
Challenges
- Side-Effects Associated with the Use
Trastuzumab Biosimilar Market: Key Insights
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
Regional Scope |
|
Trastuzumab Biosimilar Segmentation
The trastuzumab biosimilar market is segmented based on application type into breast cancer, colorectal cancer, leukemia, and others, out of which, the breast cancer segment is anticipated to grab the largest share by the end of 2021 on account of increasing incidence and increasing prevalence of breast cancer globally. Moreover, colorectal cancer segment is also projected to contribute to the growth of the segment during the forecast period due to the rising incidence in colon and rectal cancer worldwide. According to World Health Organization, the most common in 2020 (in terms of new cases of cancer) were breast cancer (2.26 million cases), followed by colon and rectum cancer (1.93 million cases) on the third number.
On the basis of distribution channel, the offline segment in the global trastumuzab biosimilar market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the presence of retail and hospital pharmacies and an expanded customer base. Although, online segment is also expected to contribute to the market due to increasing dependence on e-commerce platforms and rising internet penetration.
Our in-depth analysis of the global market includes the following segments:
|
By Application Type |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportTrastuzumab Biosimilar Industry - Regional Synopsis
Geographically, the trastuzumab biosimilar market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. Europe industry is anticipated to hold largest revenue share by 2037, owing to increasing prevalence of breast cancer, strong clinical pipeline, increasing research and drug development activities propels market growth in the region. Furthermore, in 2021, the market in Asia Pacific is evaluated to occupy the largest share in terms of revenue, Asia Pacific is a promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors to the growth of this market. Emerging and huge population base countries such as China and India offer tremendous trastuzumab biosimilar market opportunities due to investments for trastumuzab biosimilar research. As per the analysis of World Health Organization, cancer accounts for 20% of deaths in the European Region.
Companies Dominating the Trastuzumab Biosimilar Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Aryogen Biopharma
- Biocon Limited
- Celltrion Inc.
- Pfizer Inc.
- Merck & Co. Inc.
- Accord Healthcare Ltd.
- Gedeon Richter PLC
- Genor Biopharma Company Ltd.
- Mabion S.A.
- Mylan N.V.
- Roche Holding AG
In the News
Author Credits: Radhika Pawar
- Report ID: 3011
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
